Login to Your Account



Athenagen Gains New AD Platform Via Zapaq Merger

By Karen Pihl-Carey


Tuesday, July 11, 2006
Adding a new Alzheimer's disease platform to its portfolio, Athenagen Inc. agreed to merge with Zapaq Inc., a 5-year-old company focused on beta-secretase inhibitors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription